Cordatus Wealth Management LLC Sells 487 Shares of Zoetis Inc. (NYSE:ZTS)

Cordatus Wealth Management LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 5.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,159 shares of the company’s stock after selling 487 shares during the period. Cordatus Wealth Management LLC’s holdings in Zoetis were worth $1,492,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. AMF Tjanstepension AB raised its position in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after buying an additional 20,001 shares in the last quarter. Howard Capital Management Group LLC raised its position in shares of Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after buying an additional 883 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Zoetis by 8.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock valued at $10,882,000 after buying an additional 4,107 shares in the last quarter. Raleigh Capital Management Inc. raised its position in shares of Zoetis by 128.5% during the 3rd quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock valued at $71,000 after buying an additional 203 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI raised its position in shares of Zoetis by 39.6% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 2,590 shares of the company’s stock valued at $507,000 after buying an additional 735 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

NYSE:ZTS opened at $157.38 on Friday. The stock has a market cap of $70.47 billion, a PE ratio of 28.77, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business’s 50-day simple moving average is $166.86 and its two-hundred day simple moving average is $178.14. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $214.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.